Aducanumab - the Great Debate

There was a lot of excitement worldwide recently about the new drug, Aducanumab, and the effect it might have on those living with Alzheimer's. Inevitably, there was also some scepticism about its efficacy. A couple of weeks ago, a representative from the University of Cambridge School of Clinical Medicine (Cambridge Public Health) contacted Peter and asked for his views on an article written by them which was going to appear in the British Medical Journal (BMJ).

There was much head scratching, cursing and hollering in Suffolk that day when the article metaphorically landed on our laps. There were more long words in it than a Russian playing a German at an English version of Scrabble. And so here it must be stated that the article was expertly translated by our resident IT expert into a format which we could all manage to understand (sometimes having a chemistry degree and a logical brain is a wonderful asset!) Once it was distilled through the conduit of our logician and reduced to an understandable form, Peter, Teresa and I all offered our views on the drug. The article has now been published in the BMJ (see Aducanumab for Alzheimer’s disease ) complete with an acknowledgement recognising our input (you will not be judged if you scroll down to the end of the article rather than reading the whole thing!)